M&A / Deals Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation Pharmaceutical Business ReviewBofanglutide is a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) discovered and developed by Gan Lee.M&A / DealsMetabolic & GLP-1Read full story pharminent April 10, 2026 (Last updated: April 10, 2026) Pharmaceutical Business Review Bofanglutide is a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) discovered and developed by Gan Lee. M&A / DealsMetabolic & GLP-1Read full story Post navigation Previous: Precision Medicine in Early Oncology Trials: Biomarkers as Strategic DriversNext: Roche and C4 Therapeutics to advance degrader-antibody conjugates research Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026